We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.

Delisted

ITCI was delisted on the 1st of April, 2025.

91 hedge funds and large institutions have $577M invested in Intra-Cellular Therapies Inc. in 2015 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 37 increasing their positions, 17 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

261% more call options, than puts

Call options by funds: $6.08M | Put options by funds: $1.69M

213% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 8

118% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 17

43% more capital invested

Capital invested by funds: $405M → $577M (+$173M)

23% more funds holding

Funds holding: 7491 (+17)

Holders
91
Holders Change
+17
Holders Change %
+22.97%
% of All Funds
2.44%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
25
Increased
37
Reduced
17
Closed
8
Calls
$6.08M
Puts
$1.69M
Net Calls
+$4.4M
Net Calls Change
+$4.4M

ITCI Hedge Fund Activity: Q2 2015 in Review

91 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q2 2015, worth a combined $577M — up 43% from $405M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new ITCI positions and 8 closed out — a net gain of 17 holders — while 37 added to existing stakes and 17 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $12.5M. The largest seller was BlackRock Advisors, cutting an estimated $10.7M.

  • 91 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q2 2015, up from 74 in Q1 2015.
  • Funds reported $577M of Intra-Cellular Therapies Inc. stock for Q2 2015, up 43% quarter-over-quarter.
  • 25 funds opened new Intra-Cellular Therapies Inc. positions in Q2 2015 and 8 closed out, a net change of +17 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q2 2015 was Millennium Management, an estimated $12.5M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q2 2015 was BlackRock Advisors, an estimated $10.7M sold.

Based on aggregated 13F filings for Q2 2015.